|
Translated summary of immediate announcement of parent company Bio-Light Israeli Life Science Investments (TASE: BOLT)
Ramat Gan, Israel, April 23, 2009
Obecure Ltd. ("Obecure") announced the completion of its BET207 clinical trial, evaluating the safety and efficacy of Histalean™, as treatment of obesity in pre-menopausal women.
The double-blinded, placebo-controlled, dose ranging study, conducted in 12 medical centers in Germany, Belgium and the Netherlands, recruited about 180 obese women. Enrolled subjects were randomly assigned to one of three treatment groups and orally treated with 96 mg Histalean™, 48 mg Histalean™ or matching placebo, for a total duration of 12 weeks.
The Company has recently also announced the completion of a concurrent clinical trial, evaluating the potential of the drug to attenuate weight gain associated with the antipsychotic drug ZyprexaTM.
The Company is currently preparing to complete data collection in preparation for data unblinding and statistical analysis of both clinical studies. The Company expects topline results by the end of Q2 2009.
Yaffa Beck, CEO
Obecure Ltd.
5-7 Shoham St.
Ramat Gan, Israel 52521
Tel: +972-3-7534100
yaffa@bio-light.co.il |
